Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IV

Launched by SAMSUNG MEDICAL CENTER · Jun 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying patients who have been diagnosed with aggressive types of lymphoma, which is a cancer of the lymphatic system. This includes both Hodgkin lymphoma and non-Hodgkin lymphoma. The goal of the study is to follow these patients over time as they receive treatment according to the hospital’s usual care plans. Researchers will regularly check how patients are responding to treatment and track their overall health and survival. They will also collect blood samples to better understand the disease and how it changes during treatment.

People who might be eligible for this study are adults aged 20 or older who have been diagnosed with Hodgkin or non-Hodgkin lymphoma and need chemotherapy with the intent to cure the disease. Patients must be willing to provide written consent to join the study. Those with other types of blood cancers, like myeloid malignancies or multiple myeloma, or who do not need chemotherapy aimed at curing their lymphoma, are not eligible. If you join the study, you can expect to receive the standard treatment your doctors recommend while participating in regular check-ups and blood tests as part of the research. This study is currently open and enrolling patients of all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
• • 2. 20 years
• • 3. Patients requiring systemic chemotherapy with curative intent
• • 4. Written informed consent
• Exclusion Criteria:
• • 1. Myeloid malignancy
• • 2. Multiple myeloma
• • 3. Patients do not require systemic chemotherapy with curative intent